---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-098584"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-09-10T12:10:38+00:00"
generated_at: "2026-09-10T12:15:05.277148+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics to present at Stifel 2026 Virtual Immunology and Inflammation Forum

## Summary
- CEO Bradley Burnam and Dr. Stephen M. Hahn to present on September 23, 2026 at 1:30 PM ET.
- Presentation covers atopic dermatitis program, including pruritus-focused stage 2 enrichment strategy.
- Emerging findings across patient populations: moderate-severe baseline pruritus and lower EASI with high IGA.
- Live webcast on company website; replay available for approximately six months.

## SEC filing metadata
- accession: 0001213900-26-098584
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-09-10T12:10:38+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/0001213900-26-098584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/ea0305037-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-098584
- JSON: https://secwatch.observer/filing/0001213900-26-098584.json
- Plain text: https://secwatch.observer/filing/0001213900-26-098584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.